GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Debt-to-Revenue

Zai Lab (HKSE:09688) Debt-to-Revenue : 0.06 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Zai Lab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$55 Mil. Zai Lab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$63 Mil. Zai Lab's annualized Revenue for the quarter that ended in Dec. 2023 was HK$2,056 Mil. Zai Lab's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.06.


Zai Lab Debt-to-Revenue Historical Data

The historical data trend for Zai Lab's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Debt-to-Revenue Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 1.68 0.38 0.11 0.10 0.06

Zai Lab Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.07 0.06 0.06

Competitive Comparison of Zai Lab's Debt-to-Revenue

For the Biotechnology subindustry, Zai Lab's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zai Lab's Debt-to-Revenue falls into.



Zai Lab Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Zai Lab's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(55.481 + 62.845) / 2083.022
=0.06

Zai Lab's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(55.481 + 62.845) / 2056.476
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Zai Lab Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zai Lab's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab (HKSE:09688) Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Zai Lab (HKSE:09688) Headlines

No Headlines